Stocks and Investing
Stocks and Investing
Tue, February 7, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Louise Chen Reiterated (ACRS) at Buy and Held Target at $38 on, Feb 7th, 2023
Louise Chen of Cantor Fitzgerald, Reiterated "Aclaris Therapeutics, Inc." (ACRS) at Buy and Held Target at $38 on, Feb 7th, 2023.
Louise has made no other calls on ACRS in the last 4 months.
There are 2 other peers that have a rating on ACRS. Out of the 2 peers that are also analyzing ACRS, 0 agree with Louise's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Louise
- Alex Thompson of "Stifel" Initiated at Strong Buy and Held Target at $29 on, Wednesday, December 14th, 2022
- Corinne Jenkins of "Goldman Sachs" Initiated at Strong Buy and Held Target at $25 on, Thursday, December 1st, 2022
Contributing Sources